Omicron SARS-CoV-2 variant: An observational study from a hospital in Southern India

1COVID-19 Weekly Epidemiological Update (as of 16^th January 2022). Edition 75 dated 3^rd January 2022. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update COVID-19 Weekly Epidemiological Update (as of 16^th January 2022). Edition 75 dated 3^rd January 2022 Available from https://www.who.int/publications/m/item/weekly-epidemiological-updateSearch in Google Scholar

2COVID-19 Dashboard. Ministry of Health and Family Welfare, Government of India. 21^st January 2022. Available from: https://www.mohfw.nic.in COVID-19 Dashboard Ministry of Health and Family Welfare, Government of India. 21^st January 2022 Available from https://www.mohfw.nic.inSearch in Google Scholar

3World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-ofomicron-(b.1.1.529)-sars-cov-2-variant-of-concern World Health Organization Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021 Available from https://www.who.int/news/item/26-11-2021-classification-ofomicron-(b.1.1.529)-sars-cov-2-variant-of-concernSearch in Google Scholar

4Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization HQ: Headquarters, Geneva, Switzerland. Update #5: 7 January 2022. Available from: https://www.who.int/publications/m/item/enhancing-readinessfor-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization HQ: Headquarters Geneva, Switzerland Update #5: 7 January 2022. Available from https://www.who.int/publications/m/item/enhancing-readinessfor-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-statesSearch in Google Scholar

5SARS-CoV-2 (COVID-19 Virus) Variant of Concern (VoC) Screening and Genomic Sequencing for Surveillance. Public Health Ontario. Ontario Agency for Health Protection and Promotion. Updated on 20 December 2021. Available from: https://www.publichealthontario.ca/en/laboratory-services/test-information-index/covid-19-voc SARS-CoV-2 (COVID-19 Virus) Variant of Concern (VoC) Screening and Genomic Sequencing for Surveillance Public Health Ontario. Ontario Agency for Health Protection and Promotion Updated on 20 December 2021 Available from https://www.publichealthontario.ca/en/laboratory-services/test-information-index/covid-19-vocSearch in Google Scholar

6Bhatnagar T, Chaudhuri S, Ponnaiah M, Yadav PD, Sabarinathan R, Sahay RR et al. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and Delta variant in India, 2021: A case-control study. Preprint in English. Europe PMC ID: ppcovidwho-294258 Bhatnagar T Chaudhuri S Ponnaiah M Yadav PD Sabarinathan R Sahay RR et al Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and Delta variant in India, 2021: A case-control study. Preprint in English. Europe PMC ID: ppcovidwho-294258Search in Google Scholar

7Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Voysey M Clemens SAC Madhi SA Weckx LY Folegatti PM Aley PK et al Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021397 10269 99 111 10.1016/S0140-6736(20)32661-1Open DOISearch in Google Scholar

8Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill. 2021;26(50). 2101146. doi:10.2807/1560-7917.ES.2021.26.50.2101146 Espenhain L Funk T Overvad M Edslev SM Fonager J Ingham AC Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021 Euro Surveill 202126 50 2101146 10.2807/1560-7917.ES.2021.26.50.2101146Open DOISearch in Google Scholar

9S. Kannan, P. Shaik Syed Ali, A. Sheeza. Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: a mini review. European Review for Medical and Pharmacological Sciences. 2021; 25: 8019-8022. doi: 10.26355/eurrev_202112_27653 Kannan S. Shaik Syed Ali P. Sheeza A. Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: a mini review European Review for Medical and Pharmacological Sciences 2021 25 8019 8022 10.26355/eurrev_202112_27653Open DOISearch in Google Scholar

10WHO COVID-19 Dashboard. Available from: https://covid19.who.int/ WHO COVID-19 Dashboard Available from https://covid19.who.int/Search in Google Scholar

11MoHFW/COVID-19 States data/25th January2022/3. Release ID: 1792334. Available from: https://www.pib.gov.in/PressReleseDetail.aspx?PRID=1792330 MoHFW/COVID-19 States data/25th January2022/3. Release ID: 1792334 Available from https://www.pib.gov.in/PressReleseDetail.aspx?PRID=1792330Search in Google Scholar

12Clinical guidance for management of adult Covid-19 patients. AIIMS/ ICMR-COVID-19 National Task Force/ Joint Monitoring Group. Ministry of Health & Family Welfare, Government of India. 14^th January 2022. Available from URL: https://www.mohfw.gov.in/pdf/ClinicalGuidanceforManagementofAdultCovid19Patientsupdatedason17thJanuary2022.pdf Clinical guidance for management of adult Covid-19 patients AIIMS/ ICMR-COVID-19 National Task Force/ Joint Monitoring Group. Ministry of Health & Family Welfare, Government of India 14^th January 2022 Available from URL https://www.mohfw.gov.in/pdf/ClinicalGuidanceforManagementofAdultCovid19Patientsupdatedason17thJanuary2022.pdfSearch in Google Scholar

13Selvavinayagam TS, Somasundaram A, Nirmalson J, Kumar CAB, Aravintharaj S. S Gene target failure profiling – Declining third wave COVID-19. DPH Newsletter. 2022;2(3):1-4. Available from: https://www.tndphpm.com/wp-content/uploads/documents/Vol-2-Issue-3-February-01-2022-1.pdf Selvavinayagam TS Somasundaram A Nirmalson J Kumar CAB Aravintharaj S S Gene target failure profiling – Declining third wave COVID-19 DPH Newsletter 20222 3 1 4 Available from https://www.tndphpm.com/wp-content/uploads/documents/Vol-2-Issue-3-February-01-2022-1.pdfSearch in Google Scholar

14Kim MK, Lee B, Choi YY, Um J, Lee KS, Sung HK, Kim Y et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea. J Korean Med Sci. 2022; 37(3):e31. doi: 10.3346/jkms.2022.37.e31. Kim MK Lee B Choi YY Um J Lee KS Sung HK Kim Y et al Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea J Korean Med Sci 2022 37 3 e31 10.3346/jkms.2022.37.e31Open DOISearch in Google Scholar

15Kumar RM, Vivian TJW, Selvavinayagam TS, Somasundaram A, Parthipan K, Raju S et al. Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022. Indian Journal of Medical Research 2022;155(1):1-6. doi: 10.4103/ijmr.ijmr_312_22 Kumar RM Vivian TJW Selvavinayagam TS Somasundaram A Parthipan K Raju S et al Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022 Indian Journal of Medical Research 2022155 1 1 6 10.4103/ijmr.ijmr_312_22Open DOISearch in Google Scholar

16Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. European Review for Medical and Pharmacological Sciences. 2021;25(24):8012-18. doi.org/10.26355/eurrev_202112_27652 Meo SA Meo AS Al-Jassir FF Klonoff DC Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics European Review for Medical and Pharmacological Sciences 202125 24 8012 18 doi.org/10.26355/eurrev_202112_27652Search in Google Scholar

17National Institute for Communicable Diseases. South African COVID-19 Weekly Epidemiology Brief: week 52 2021. National Institute for Communicable Diseases (NICD) South Africa; 2022. Available from: https://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-Epi-Brief_Week52.pd National Institute for Communicable Diseases South African COVID-19 Weekly Epidemiology Brief: week 52 2021. National Institute for Communicable Diseases (NICD) South Africa; 2022 Available from https://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-Epi-Brief_Week52.pdSearch in Google Scholar

18Sharma RP, Gautam S, Sharma P, Singh R, Sharma H, Parsoya D et al. Clinico epidemiological profile of Omicron variant of SARS CoV2 in Rajasthan. medRxiv 2022.02.11.22270698; doi: https://doi.org/10.1101/2022.02.11.22270698 Sharma RP Gautam S Sharma P Singh R Sharma H Parsoya D et al Clinico epidemiological profile of Omicron variant of SARS CoV2 in Rajasthan medRxiv 202202.11.22270698; https://doi.org/10.1101/2022.02.11.22270698Open DOISearch in Google Scholar

19Ewen Callaway. The race for coronavirus vaccines: a graphical guide. Nature 2000;580(7805):576. Ewen Callaway The race for coronavirus vaccines: a graphical guide Nature 2000580 7805 57610.1038/d41586-020-01221-ySearch in Google Scholar

20WHO target product profiles for COVID-19 vaccines. April 9, 2020. Available from: https:// www.who.int/publications/m/item/who target-product-profiles-for-covid-19-vaccines. WHO target product profiles for COVID-19 vaccines April 9, 2020. Available from https://www.who.int/publications/m/item/whotarget-product-profiles-for-covid-19-vaccinesSearch in Google Scholar

21Bartsch SM, O’Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am J Prev Med 2020;59: 493–503. Bartsch SM O’Shea KJ Ferguson MC et al Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention Am J Prev Med 202059 493 50310.1016/j.amepre.2020.06.011Search in Google Scholar

22Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization HQ: Headquarters, Geneva, Switzerland. Update #5: 7 January 2022. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization HQ: Headquarters Geneva, Switzerland Update #5: 7 January 2022. Available from https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-statesSearch in Google Scholar

23Dejnirattisai W, Huo J,Zhou D, Zahradník J, Supasa P, Liu C. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Epub ahead of print bioRxiv 2021.12.03.471045; doi: https://doi.org/10.1101/2021.12.03.471045 Dejnirattisai W Huo JZhou D Zahradník J Supasa P Liu C Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Epub ahead of print bioRxiv 202112.03.471045; https://doi.org/10.1101/2021.12.03.471045Open DOISearch in Google Scholar

24Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.The Lancet 2022:399 (10335):1618-24. doi: https://doi.org/10.1016/S0140-6736(22)00327-0 Menni C Valdes AM Polidori L Antonelli M Penamakuri S et al Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study The Lancet 2022399 10335 1618 24 https://doi.org/10.1016/S0140-6736(22)00327-0Open DOISearch in Google Scholar

25Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Karim SSA Karim QA Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic Lancet 2021398 10317 2126 2128 10.1016/S0140-6736(21)02758-6Open DOISearch in Google Scholar